Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer

Scientific Reports

Volumn 4, Issue , 2014, Pages

  McGuire, Michael J ^a,c   Gray, Bethany Powell ^a,c   Li, Shunzi ^a,c   Cupka, Dorothy ^a,c   Byers, Lauren Averett ^d   Wu, Lei ^a,c   Rezaie, Shaghayegh ^a,c   Liu, Ying Horng ^a,c   Pattisapu, Naveen ^a,c   Issac, James ^a,c   Oyama, Tsukasa ^a   Diao, Lixia ^d   Heymach, John V ^d   Xie, Xian Jin ^b,c   Minna, John D ^a,b,c   Brown, Kathlynn C ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; PEPTIDE; PEPTIDE LIBRARY; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANIMAL; CELL SURFACE DISPLAY; CHEMICAL STRUCTURE; CHEMISTRY; CLUSTER ANALYSIS; DISEASE MODEL; DRUG DELIVERY SYSTEM; GENETICS; GENOTYPE; HUMAN; LUNG TUMOR; METABOLISM; MOUSE; NON SMALL CELL LUNG CANCER; PATHOLOGY; PEPTIDE LIBRARY; PHENOTYPE; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; TUMOR CELL LINE; XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURFACE DISPLAY TECHNIQUES; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GENOTYPE; HETEROGRAFTS; HUMANS; LIGANDS; LUNG NEOPLASMS; MICE; MOLECULAR STRUCTURE; PEPTIDE LIBRARY; PEPTIDES; PHENOTYPE; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT;

EID: 84897095746     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04480     Document Type: Article

References (35)

1. Siegel, R. et al. Cancer treatment and survivorship statistics, 2012. CA. Cancer J. Clin. 62, 220-241 (2012).
2. Brambilla, E. & Gazdar, A. Pathogenesis of lung cancer signaling pathways: Roadmap for therapies. Eur. Respir. J. 33, 1485-1497 (2009).
3. Chung, C. H. et al. Cetuximab-induced anaphylaxis and ige specific for galactosea-1,3-galactose. N. Engl. J. Med. 358, 1109-1117 (2008).
4. Bray, B. L. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discov. 2, 587-593 (2003).
5. Nagy, A. & Schally, A. V. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: A "smarter" therapy. Curr. Pharm. Des. 11, 1167-1180 (2005).
6. Aina, O. H. et al. From combinatorial chemistry to cancer targeting peptides. Mol. Pharm. 4, 631-651 (2007).
7. Brown, K. C. Peptidic tumor targeting agents: The road from phage display peptide selections to clinical applications. Curr. Pharm. Des. 16, 1040-1054 (2010).
8. Gray, B. P. & Brown, K. C. Combinatorial peptide libraries: Mining for cellbinding peptides. Chem. Rev. 114, 1020-1081 (2014).
9. De, J. et al. Isolation of a Mycoplasma-specific binding peptide from an unbiased phage-displayed peptide library. Mol. Biosyst. 1, 149-157 (2005).
10. Mcguire, M. J., Li, S.amp;&Brown, K. C. (2009) Biopanning of phage displayed peptide libraries for the isolation of cell-specific ligand, In Biosensors and Biodetection Methods and Protocols (Walker, J. M., Ed.), pp 291-321. Humana Press, New York.
11. Mcguire, M. J., Samli, K. N., Chang, Y. & Brown, K. C. Novel ligands for cancer diagnosis: Selection of peptide ligands for identification and isolation of B-cell lymphomas. Exp. Hematol. 34, 443-452 (2006).
12. Mcguire, M. J., Samli, K. N., Johnston, S. A. & Brown, K. C. In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo. J. Mol. Biol. 342, 171-182 (2004).
13. Mcguire,M. J. et al. A library selected Langerhans cell-targeting peptide enhances an immune response. DNA Cell Biol. 23, 742-752 (2004).
14. Oyama, T. et al. Isolation of multiple cell-binding ligands from different phage displayed-peptide libraries. Biosens. Bioelectron. 21, 1867-1875 (2006).
15. Oyama, T. et al. Isolation of lung tumor specific peptides from a random peptide library: Generation of diagnostic and cell-targeting reagents. Cancer Lett. 202, 219-230 (2003).
16. Li, S. et al. Synthesis and characterization of a high affinity avb6-specific ligand for in vitro and in vivo applications Mol. Cancer Ther. 8, 1239-1249 (2009).
17. Ramirez, R. D. et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 64, 9027-9034 (2004).
18. Byers, L. A. et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279-290 (2013).
19. Byers, L. A. et al. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin. Cancer Res. 15, 6852-6861 (2009).
20. Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712 (1989).
21. Chang, D.-K., Lin, C.-T., Wu, C.-H. & Wu, H.-C. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS ONE 4, e4171 (2009).
22. Zang, L. et al. Screening and identification of a peptide specifically targeted to NCI-H1299 from a phage display peptide library. Cancer Lett. 281, 64-70 (2009).
23. Kolonin, M. G. et al. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res. 66, 34-40 (2006).
24. Elayadi, A. N. et al.Apeptide selected by biopanning identifies the integrin avb6 as a prognostic biomarker for non-small cell lung cancer. Cancer Res. 67, 5889-5895 (2007).
25. Ramos, D. M., Dang, D. & Sadler, S. The role of the integrin alphav beta6 in regulating the epithelial to mesenchymal transition in oral cancer. Anticancer Res. 29, 125-130 (2009).
26. Bates, R. C. et al. Transcriptional activation of integrin b6 during the epithelialmesenchymal transition defines a novel prognostic indicator of aggressive colon cancer. J. Clin. Invest. 115, 339-347 (2005).
27. Ahmed, N. et al. avb6 Integrin-a marker for the malignant potential of epithelial ovarian cancer. J. Histochem. Cytochem. 50, 1371-1379 (2002).
28. Hazelbag, S. et al. Overexpression of the avb6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J. Pathol. 212, 316-324 (2007).
29. Yang, G.-Y. et al. Integrin alphavbeta6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver. Cancer Sci. 99, 879-887 (2008).
30. Prudkin, L. et al. Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous carcinoma of the lung. Mod. Pathol. 22, 668-678 (2009).
31. Bierie, B. &Moses, H. L. Tumour microenvironment: TGFb: The molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6, 506-520 (2006).
32. Annes, J., Chen, Y., Munger, J. & Rikfin, D. Integrin avb6-mediated activation of latent TGF-b requires the latenr TGF-b binding protein-1. J. Cell Biol. 165, 723-734 (2004).
33. Worthington, J., Klementowicz, J. & Travis, M. TGFb: A sleeping giant awoken by integrins. Trends Biochem. Sci. 36, 47-54 (2011).
34. Phelps, R. M. et al. NCI-Navy medical oncology branch cell line database. J. Cell. Biochem. 63, 32-91 (1996).
35. Cwirla, S. E., Peters, E. A., Barrett, R. W. & Dower, W. J. Peptides on phage: A vast library of peptides for identifying ligands. Proc. Natl. Acad. Sci. U. S. A. 87, 6378-6382 (1990).